REG - Allergy Therapeutics - Appointment of Interim CFO

Allergy TherapeuticsAnnouncement

21/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221121:nRSU9863Ga&default-theme=true

RNS Number : 9863G  Allergy Therapeutics PLC  21 November 2022

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

Appointment of Interim CFO

 

21 November 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, today
announces the appointment of Martin Hopcroft to the role of Interim Chief
Financial Officer (CFO). Martin will report into Chief Executive Officer,
Manuel Llobet.

 

Martin brings significant financial experience across multiple industries. He
served as CFO of Novasep SA, a supplier of pharmaceuticals and
biopharmaceuticals, and during his tenure Novasep won a major contract with
AstraZeneca to support the large-scale production of the active substance of
its adenovirus vector-based COVID-19 vaccine. Martin previously served as CFO
of formerly listed Cambian Group plc, a provider of specialist residential and
educational services for children and young adults, and of Consort Medical
plc, a medical devices company.

 

The appointment of Martin Hopcroft follows the announcement on 26 May 2022
that Nick Wykeman, CFO, will leave Allergy Therapeutics on 30 November 2022 to
pursue non-executive roles. The Group is continuing its search for a permanent
CFO and will make a further announcement in due course.

 

Manuel Llobet, Chief Executive Officer, commented: "Martin is a highly
experienced executive and it is my pleasure to welcome him to Allergy
Therapeutics' senior management team. I also want to take this opportunity to
again thank Nick Wykeman for his work and dedication over the past six years
and I wish him the very best for his future."

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which has
achieved over 9% compound annual growth since formation, employs c.600
employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDGBDBIUDDGDG